Related to UPenn Alumni Gift $25M for Facility Focused on BRCA-Mutated Cancers

• Morphotek Taps Synageva in Cancer and Infectious Disease Deal
  
• Repros Gets an Extension from NIH for Deadlines Related to Lead Anticancer Agent
  
• OSI to Pay $20M to Broaden Cancer Partnership with AVEO
  
• GSK and Enigma to Develop Point-of-Care Flu Diagnostic
  
• BioFocus DPI and Oncodesign Ally to Provide Oncology Drug Discovery Services
  
• Apogenix Obtains Roughly $3.66M to Further Cancer and Inflammatory Disease Initiatives
  
• ImmunoVaccine Technologies Collaborates with Scancell to Advance DNA Vaccine Delivery
  
• Horizon Gains Patents to Cell Lines that Model Genetic Mutations Seen in Cancer
  
• Vernalis Earns $6M Up Front in Oncology Deal with GSK
  
• Viral Genetics Forms Anticancer Subsidiary to Exploit Metabolic Disruption Technology
  
• Rosetta Genomics Taps Warnex as Canadian Distributor for Cancer Diagnostics
  
• Facet Biotech Steps Up to Help Trubion Advance Early-Stage Anticancer Agent with a $20M Fee
  
• Scientists Uncover Molecular Pathway that Makes Tumors More Aggressive
  
• BioMarker Strategies Secures $1.7M to Expedite Live Tumor Cell Testing System
  
• Access Pharma Taps Accupac to Manufacture Oral Mucositis Therapy in North America
  
• Karus Taps Queen Mary, University of London's Expertise for PI3K Inhibitor Development
  
• Altor Scores $3M NCI Grant for Clinical Development of IL-2 Boosting Drug
  
• Roche Sequence Capture and Genome Sequencing Technologies to Be Evaluated for Cancer Genetics
  
• Sanofi-Aventis Gains License to Phase I Anticancer Agent from Merrimack for $60M Up Front
  
• Polish University to Use Cellectricon’s Transfection System